Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover Meeting Abstract

sustainable development goals

authors

publication date

  • January 1, 2016

webpage

published in

start page

  • 84

end page

  • 84

volume

  • 103